Drug Profile

OC 001

Alternative Names: OC-001

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ocellaris Pharma
Class Antineoplastics; Immunotherapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Cancer

Most Recent Events

28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in USA (IV)
09 Sep 2022 Adverse event and Pharmacokinetics data from a phase I/II trial in Cancer presented at the 47^th European Society for Medical Oncology Congress (ESMO-2022)
19 Aug 2020 Phase-I/II clinical trials in Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in Canada (IV) (NCT04260802)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com